United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 301 shares of United Therapeutics stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $110.48, for a total value of $33,254.48. Following the transaction, the chief executive officer now owns 21,652 shares in the company, valued at approximately $2,392,112.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
United Therapeutics Co. (NASDAQ UTHR) traded down $0.09 during midday trading on Friday, reaching $108.33. The company’s stock had a trading volume of 7,060 shares, compared to its average volume of 445,606. The company has a market cap of $4,715.72, a PE ratio of 9.94 and a beta of 1.32. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. United Therapeutics Co. has a 12-month low of $106.30 and a 12-month high of $152.55.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.59 by $0.30. The firm had revenue of $464.70 million for the quarter, compared to analysts’ expectations of $420.55 million. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.12 EPS. sell-side analysts forecast that United Therapeutics Co. will post 12.46 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on UTHR shares. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. ValuEngine cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a report on Monday, January 15th. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, Oppenheimer lifted their price objective on United Therapeutics to $180.00 and gave the company an “outperform” rating in a report on Friday, January 5th. Five research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $135.20.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after acquiring an additional 189,378 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of United Therapeutics by 2.4% during the 4th quarter. Acadian Asset Management LLC now owns 1,121,068 shares of the biotechnology company’s stock worth $165,861,000 after purchasing an additional 26,122 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of United Therapeutics by 9.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock worth $93,531,000 after purchasing an additional 71,333 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of United Therapeutics by 2.0% during the 4th quarter. Wells Fargo & Company MN now owns 744,312 shares of the biotechnology company’s stock worth $110,120,000 after purchasing an additional 14,593 shares during the last quarter. Finally, APG Asset Management N.V. increased its position in shares of United Therapeutics by 8.3% during the 4th quarter. APG Asset Management N.V. now owns 705,900 shares of the biotechnology company’s stock worth $86,974,000 after purchasing an additional 53,900 shares during the last quarter.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.